Ultragenyx Pharmaceutical Balance Sheet
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical financial position
At the end of fiscal 2025, Ultragenyx Pharmaceutical reported total assets of $1.53 billion, up 1.9% from a year earlier against total liabilities of $1.60 billion. Shareholders' equity was negative at -$80.0 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $421.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.48, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 421.00M | 174.00M | 214.00M | 132.94M | 307.58M | 713.53M | 433.58M | 113.43M | 100.49M | 161.12M |
| Short-Term Investments | 259.00M | 436.00M | 363.63M | 614.82M | 432.61M | 488.01M | 321.65M | 346.27M | 134.00M | 219.03M |
| Receivables | 158.00M | 122.00M | 73.39M | 40.45M | 28.43M | 23.09M | 32.84M | 12.74M | 5.17M | — |
| Inventory | 52.00M | 45.00M | 33.97M | 26.77M | 16.23M | 13.05M | 11.55M | 7.07M | 757.00K | — |
| Total Current Assets | 951.00M | 817.00M | 732.18M | 883.90M | 856.60M | 1.30B | 851.02M | 522.37M | 269.58M | 401.69M |
| Property, Plant & Equipment | 244.00M | 266.00M | 290.57M | 259.73M | 141.25M | 73.52M | 44.35M | 20.05M | 21.84M | 17.05M |
| Goodwill | 44.00M | 44.00M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | — |
| Intangible Assets | 176.00M | 178.00M | 166.27M | 160.10M | 130.79M | 131.11M | 129.00M | 129.22M | 141.54M | — |
| Long-Term Investments | 57.00M | 135.00M | 199.90M | 148.97M | 258.93M | 10.51M | 5.17M | — | 9.97M | 117.96M |
| Total Assets | 1.53B | 1.50B | 1.49B | 1.55B | 1.52B | 1.76B | 1.14B | 719.56M | 490.75M | 540.63M |
| Accounts Payable | 31.00M | 39.00M | 42.11M | 43.27M | 17.14M | 12.92M | 12.87M | 12.28M | 8.89M | 5.36M |
| Total Current Liabilities | 384.00M | 344.00M | 280.44M | 261.21M | 181.37M | 189.61M | 103.30M | 74.72M | 71.01M | 60.26M |
| Total Liabilities | 1.60B | 1.24B | 1.22B | 1.19B | 599.84M | 605.18M | 481.73M | 110.65M | 107.30M | 66.65M |
| Shareholders' Equity | -80.00M | 255.00M | 275.00M | 352.00M | 922.56M | 1.15B | 653.76M | 608.91M | 383.45M | 473.97M |
| Retained Earnings | -4.53B | -3.96B | -3.39B | -2.78B | -2.07B | -1.62B | -1.43B | -1.03B | -832.67M | -530.53M |
| Net Cash (Debt) | 680.00M | 610.00M | 577.63M | 747.76M | 740.20M | 1.20B | 755.23M | 459.71M | 234.49M | 380.15M |
| Shares Outstanding | 96.60M | 92.50M | 82.32M | 70.20M | 69.34M | 66.82M | 57.84M | 50.86M | 44.17M | 41.24M |
This table shows 10 annual periods of Ultragenyx Pharmaceutical's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a balance sheet?